Amneal Pharmaceuticals, Inc. (AMRX) Stock Price & Analysis
Amneal Pharmaceuticals, Inc. (AMRX) closed at USD 20.48 on Thursday, October 22, 2026, up 1.39% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 20.2; the Oct 22, 2026 session ranged USD 20.21–20.58 on volume of 6,035,674 shares. Market capitalization is $7.13B, with a 52-week range of USD 9.99–21.18 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AMRX.md
Key facts (AMRX)
- Last four reported quarters (through Jun 30, 2026): revenue $3.12B, net income $157M (5.0% margin), free cash flow $128M (SEC filings).
- Valuation: P/E 45.3x (avg 56.8x at the last 1 fiscal year-ends), net debt $2.44B.
- Earnings quality: non-operating income -$253M vs operating income $454M over the last four quarters; P/E excluding non-operating income ≈17.4x (estimate: non-operating income taxed at the company's 0% effective rate).
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $7.7M; 4 not under a Rule 10b5-1 plan ($7.7M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.57 on a 1–5 scale) (7 analysts), mean target USD 23 (range 20–27).
- Total return with dividends: 1Y +96.5% vs S&P 500 +14.9%; 5Y +261.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.24, revenue estimate $814M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (AMRX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.09B | $2.21B | $2.39B | $2.79B | $3.02B | $3.12B |
| Gross profit | $769M | $785M | $821M | $1.02B | $1.11B | — |
| Operating income | $153M | -$94.9M | $204M | $249M | $394M | $454M |
| Net income | $13.2M | -$271M | -$84.0M | -$117M | $72.1M | $157M |
| EPS (diluted) | $0.07 | -$0.86 | -$0.48 | -$0.38 | $0.22 | — |
| Free cash flow | $194M | $18.7M | $302M | $243M | $270M | $128M |
| Gross margin | 36.7% | 35.5% | 34.3% | 36.5% | 36.9% | — |
| Operating margin | 7.3% | -4.3% | 8.5% | 8.9% | 13.1% | 14.6% |
| Net margin | 0.6% | -12.2% | -3.5% | -4.2% | 2.4% | 5.0% |
| Revenue growth | +5.1% | +5.7% | +8.2% | +16.7% | +8.0% | — |
| Cash + short-term investments | $248M | $26.0M | $91.5M | $111M | $282M | — |
| Total debt | $2.71B | $2.62B | $2.42B | $2.39B | $2.57B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (AMRX)
P/E 45.3x · P/E ex non-operating (est.) ≈17.4x · P/S 2.3x · EV/Sales 3.1x · P/FCF 55.8x · P/B 216.0x · FCF yield 1.79% · Earnings yield 2.21% · Net debt $2.44B · EV $9.58B
P/E at fiscal year-ends: Dec 2025 56.8x.
Insider sales (SEC Form 4, open-market, last ~7 months) (AMRX)
0 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-13 | Kiely John | Director | 50,000 | $882K | 20% | No | Too little history (no open-market trades in 2023) |
| 2026-08-12 | Shah Nikita | Executive Vice President | 146,403 | $2.6M | 36.6% | No | Too little history (no open-market trades in 2023) |
| 2026-08-11…2026-08-12 | Daly Jason B. | EVP, Chief Legal Officer | 216,613 | $3.8M | 86% | No | Too little history (no open-market trades in 2023) |
| 2026-05-11 | Autor Deborah M. | Director | 34,819 | $451K | 27.1% | No | Too little history (no open-market trades in 2023 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (AMRX)
Consensus Buy (mean 1.57 on a 1–5 scale), 7 analysts; mean target USD 23 (low 20, high 27).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | JP Morgan | Target raised | Overweight | $22 → $24 |
| 2026-09-23 | Oppenheimer | Initiated | Outperform | $27 |
| 2026-09-17 | Barclays | Target raised | Overweight | $16 → $20 |
| 2026-09-09 | Leerink Partners | Initiated | Outperform | $23 |
| 2026-08-03 | UBS | Target raised | Buy | $23 → $25 |
| 2026-07-15 | UBS | Target raised | Buy | $19 → $23 |
Total return (dividends reinvested) (AMRX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +96.5% | +261.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +97.0% | +29.2% |
| Volatility (annualized) | 35.6% | 46.6% |
| Max drawdown | -22.3% (Feb 2026→May 2026) | -76.5% (Oct 2021→Mar 2023) |
AMRX revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Affordable Medicines | $489.9M | 61.5% | +13.0% |
| AvKARE | $157.0M | 19.7% | -3.7% |
| Specialty | $149.3M | 18.8% | +16.6% |
| Specialty | $149.3M | 18.8% | +16.6% |
| Total revenue | $796.2M | 100% | — |
AMRX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Subtotal Dosage Forms | $482.3M | 60.6% | +11.8% |
| Oral Solid | $175.2M | 22.0% | -1.7% |
| Subtotal Therapeutic Classes | $149.3M | 18.8% | +17.1% |
| Central Nervous System | $95.3M | 12.0% | +14.3% |
| Distribution Service | $86.9M | 10.9% | -12.8% |
| Other Dosage Forms | $81.6M | 10.2% | +19.7% |
| Transdermal | $67.0M | 8.4% | +64.7% |
| Ephinephrine Auto Injector | $62.2M | 7.8% | -6.6% |
| Injectable | $56.8M | 7.1% | +63.9% |
| Government Label | $50.2M | 6.3% | +10.5% |
| Hormonal Allergy | $42.1M | 5.3% | +18.9% |
| Biosimilar | $29.1M | 3.7% | +15.4% |
| Institutional | $12.1M | 1.5% | +19.5% |
| Other Therapeutic Classes | $11.9M | 1.5% | +36.2% |
| Oral Liquid | $10.4M | 1.3% | -42.0% |
| Product & Service Other | $7.7M | 1.0% | -1.1% |
| International | $7.6M | 1.0% | +300.5% |
| Total revenue | $796.2M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
AMRX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Kashiv Biosciences | “In December 2022, we entered into a development and supply agreement specific to four generic product candidates with Kashiv Biosciences LLC ("Kashiv").” |
| Supplier | Zambon Biotech | “On February 23, 2024, we entered into a license, distribution and supply agreement with Zambon Biotech S.A. ("Zambon") granting Zambon the exclusive rights to seek regulatory approval and commercialize IPX203 in Europe (the "Zambon License Agreement").” |
| Supplier | Knight Therapeutics International | “On January 24, 2024, we entered into a 15-year license, distribution and supply agreement with Knight Therapeutics International S.A. ("Knight") granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America (the "Knight License Agreement").” |
| Supplier | Metsera | “Our 2026 estimate is net of expected contributions from Metsera, Inc. under our collaboration and supply agreement.” |
| Customer | McKesson (MCK) | “For the year ended December 31, 2025, our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, collectively accounted for approximately 71% of our consolidated net revenue.” |
| Customer | Cardinal Health (CAH) | “For the year ended December 31, 2025, our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, collectively accounted for approximately 71% of our consolidated net revenue.” |
| Customer | AvKARE | “Refer to "AvKARE" in the "Segments of the Business" section above for a description of customers served by our AvKARE segment.” |
| Customer | Cencora (COR) | “For the year ended December 31, 2025, our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, collectively accounted for approximately 71% of our consolidated net revenue.” |
| Customer | CVS HEALTH Corp (CVS) | “For the year ended December 31, 2025, our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, collectively accounted for approximately 71% of our consolidated net revenue.” |
| Partner | Orion Group Holdings Inc (ORN) | “Orion Corporation License Agreement” |
| Partner | ApiJect Systems | “On May 8, 2025, we entered into a 15-year strategic collaboration agreement with ApiJect Systems, Corp. and related entities ("ApiJect"), a medical technology company focused on advanced drug delivery ("ApiJect Agreement").” |
| Partner | Valorum Oncology | “In December 2025, we entered into a distribution agreement with Valorum Oncology, LLC ("Valorum"), under which Valorum serves as exclusive distributor of ALYMSYS® in the U.S. and Puerto Rico.” |
| Partner | CVS Health (CVS) | “For example, large wholesalers and retailer customers have formed alliances, such as Walgreens and Cencora, Inc., Rite Aid and McKesson Drug Company, and CVS Caremark and Cardinal Health.” |
| Related party | TPG Operations | “A partner in TPG Capital was an observer of our Board of Directors until July 2025, at which time TPG Capital ceased to be a related party.” |
| Competitor | Pfizer (PFE) | “Our principal competitors in the generic and biosimilar pharmaceutical market include Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz Group, Pfizer Inc., Fresenius Kabi KGaA, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Amphastar Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Zydus Pharmaceuticals USA Inc., and Aurobindo Pharma Limited.” |
| Competitor | AbbVie (ABBV) | “Our principal competitors in the specialty pharmaceutical market include Supernus Pharmaceuticals, Inc., Jazz Pharmaceuticals PLC, AbbVie Inc., and Alkermes PLC.” |
Quoted from the company's 10-K filed Feb 27, 2026.
Companies that name AMRX in their SEC reports
| Relationship to AMRX | Company | Filing | Sentence |
|---|---|---|---|
| partner | Vanda Pharmaceuticals Inc. (VNDA) | 10-K Feb 12, 2026 | “In January 2023, MSN and its commercial partner, Amneal Pharmaceuticals, Inc., informed us of their belief that such circumstances have occurred and have since launched their generic version.” |
AMRX customer concentration
In the period ended Jun 30, 2026, 3 direct customers each accounted for at least 10% (23%, 21%, 16%) of revenue, per the company's 10-Q filed Aug 6, 2026. The company does not name them.
AMRX company outlook (results filed Jul 30, 2026)
- “Full Year Guidance – – Successful Debt Repricing in July Reduces Interest Cost – BRIDGEWATER, NJ, July 30, 2026 - Amneal Pharmaceuticals, Inc.”
- “This robust first-half performance gives us confidence to raise our full-year 2026 guidance for the second time this year.”
- “As we look ahead to the remainder of 2026, 2027 and beyond, we remain highly confident in Amneal's outlook and the breadth and durability of the opportunities across our portfolio," said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.”
Quoted word-for-word from the SEC 8-K results press release.
AMRX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.24 | $0.25 | -4.1% | $814.1M | 7 |
| Next quarter (ends Dec 2026) | $0.22 | $0.25 | -10.4% | $823.8M | 7 |
| Current fiscal year (ends Dec 2026) | $1.03 | $0.98 | +4.9% | $3.16B | 7 |
| Next fiscal year (ends Dec 2027) | $1.20 | $1.12 | +7.4% | $3.45B | 7 |
Key Statistics (as of October 23, 2026 at 09:48 UTC)
| Price | USD 20.48 |
|---|---|
| Change | ▲ 1.39% (up) |
| Previous Close | USD 20.2 |
| Open | USD 20.32 |
| Day Range | USD 20.21 – 20.58 |
| 52-Week Range | USD 9.99 – 21.18 |
| Volume | 6,035,674 shares |
| Market Cap | $7.13B |
| Exchange | NMS |
Technical Analysis (AMRX)
Nexqual's technical model rates AMRX "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 63.56 (neutral) |
| vs SMA50 | Above (USD 18.75) |
| MACD | 0.3 (positive) |
Analyst Ratings (AMRX)
Wall Street analysts rate AMRX "Buy" based on 7 analysts, with a mean price target of USD 23 (range USD 20–27), per Nexqual as of October 23, 2026 at 09:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 23 |
| High Target | USD 27 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (AMRX)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.24 |
| Revenue Estimate | $814.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.3 vs est 0.23 ▲ beat |
| 2026-03-31 | USD 0.27 vs est 0.17 ▲ beat |
| 2025-12-31 | USD 0.21 vs est 0.18 ▲ beat |
| 2025-09-30 | USD 0.17 vs est 0.14 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financials & Fundamentals (AMRX)
| Total Revenue | $3.12B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +9.90% |
| Gross Margin | +39.81% |
| Operating Margin | +18.34% |
| Profit Margin | +5.05% |
| ROE | +613.02% |
| Debt / Equity | 23.87 |
| Current Ratio | 2.21 |
| Total Cash | $131.41M |
| Total Debt | $2.79B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $127.83M (4.1% of revenue) |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Financial Health Score (AMRX)
Nexqual rates Amneal Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:48 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 40%, operating 18% (last 12 months) |
| Balance Sheet | Weak — $128M cash and investments vs $2.57B debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $128M (last 4 quarters to Jun 2026, SEC), slim 4.1% margin |
| Efficiency | Strong — ROE 613%, ROA 8.6% |
Ownership (AMRX)
| Insider Ownership | +52.10% |
|---|---|
| Institutional Ownership | +48.77% |
| Shares Outstanding | 348.30M |
| Float | 197.33M |
| Short % of Float | +4.60% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
Leadership (AMRX)
Amneal Pharmaceuticals, Inc. is led by Chirag K. Patel, Co-Founder, Co-CEO, President & Director, per Nexqual as of October 23, 2026 at 09:48 UTC.
| Co-Founder, Co-CEO, President & Director | Chirag K. Patel |
|---|---|
| Co-Founder, Co-CEO & Director | Chintu Patel R.Ph. |
| Executive VP & CFO | Anastasios G. Konidaris |
| Senior Director of Corporate Communications | Brandon Skop |
| Senior Vice President of Corporate Development | Gregory Sgammato |
Major Backers & Investors (AMRX)
Notable institutional backers of Amneal Pharmaceuticals, Inc. include TPG GP A, LLC, Rubric Capital Management LP, Morgan Stanley, according to Nexqual as of October 23, 2026 at 09:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TPG GP A, LLC | 4.02% |
| Rubric Capital Management LP | 3.32% |
| Morgan Stanley | 1.34% |
| Neuberger Berman Group, LLC | 1.27% |
| Invesco | 0.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.67% |
| Vanguard Group | 6.48% |
| State Street | 2.4% |
| Dimensional Fund Advisors | 1.89% |
| Geode Capital | 1.68% |
Source: Nexqual, October 23, 2026 at 09:48 UTC.
From Amneal Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- By focusing on our high-value products with complex dosage forms and high barriers-to-entry, as well as taking advantage of our vertically integrated supply chain and selective use of internal API, we aim to manufacture more profitable products relative to our competition.
- The agreement also grants the Company an exclusive license to commercialize certain Metsera products in select emerging markets, including India, certain Southeast Asian countries, Africa, and the Middle East.
- ONGENTYS® is BIAL's proprietary, once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor approved by the FDA in 2020 as an add-on treatment to carbidopa/levodopa in patients with Parkinson's disease experiencing "off" episodes.
- Generic pharmaceutical products have the same API, dosage form, strength, route of administration, and conditions of use as patented branded pharmaceutical products, are bioequivalent to the brand it copies, and are usually marketed under their chemical (generic) names rather than brand names.
Partnerships
- On February 23, 2024, we entered into a license, distribution and supply agreement with Zambon Biotech S.A. ("Zambon") granting Zambon the exclusive rights to seek regulatory approval and commercialize IPX203 in Europe (the "Zambon License Agreement").
- On January 24, 2024, we entered into a 15-year license, distribution and supply agreement with Knight Therapeutics International S.A. ("Knight") granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America (the "Knight License Agreement").
Legal & Regulatory Risks (Item 1A, quoted)
- We are involved in various legal proceedings and may be involved in future legal proceedings, all of which are uncertain, and existing and future proceedings may require us to incur substantial expense to defend and/or expose us to substantial liability.
- The development, manufacture and sale of our drug products involves an inherent risk of product liability and other claims and the associated adverse publicity, and insurance against such potential claims is expensive and may be difficult to obtain.
- We are subject to United States federal and state laws related to healthcare fraud and abuse and health information privacy and security, and the failure to comply with such laws may adversely affect our business.
- The domestic and foreign laws that may affect our ability to operate include, but are not limited to: (i) the U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALKS | Alkermes plc | USD 44.18 | ▲ 1.61% |
| HIMS | Hims & Hers Health, Inc. | USD 29.13 | ▼ 0.27% |
| LNTH | Lantheus Holdings, Inc. | USD 100.1 | ▼ 0.14% |
| KNSA | Kiniksa Pharmaceuticals Interna | USD 80.79 | ▲ 1.37% |
| RGC | Regencell Bioscience Holdings L | USD 9.81 | ▼ 9.17% |
| RDY | Dr. Reddy's Laboratories Ltd | USD 13.23 | ▲ 0.3% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt